Vancouver, BC – Amphoraxe Life Sciences Inc., together with academic partners, today announced the launch of the SEAPF (Safe and Effective Antimicrobials for Poultry Farming) Project, supported through Agriculture and Agri-Food Canada’s (AAFC) AgriScience Program – Projects component, with AAFC investing up to $892,122.
Antimicrobial resistance (AMR) is recognized as a growing national and global threat to human and animal health, food security, and trade. At the same time, Canada has tightened regulations on the use of medically important antibiotics in livestock, creating an urgent need for effective, practical alternatives for farmers.
The SEAPF Project will develop and advance antimicrobial peptide (AMP) formulations as sustainable, antibiotic-alternative tools to help prevent and control bacterial disease in poultry. Over the three-year project, the team will develop cost-effective, scalable manufacturing methods for lead AMPs and characterize their bioactivity in the laboratory, preparing the technology for future on-farm deployment.
“Canadian poultry farmers were asked to give up traditional antibiotics that helped keep their flocks healthy without having viable, science-based tools in hand. With SEAPF, we are working to deliver Canadian-made solutions that help protect animal health, support food safety, and maintain the competitiveness of our supply-managed poultry sector.”
“The SEAPF Project shows how Canadian genomics and data science can be harnessed to solve real-world problems in agriculture. By combining advanced molecular tools with strong industry partnerships, we can accelerate the development of next-generation antimicrobials.”
“Partnerships like SEAPF are essential if we want to keep Canadian farms productive and resilient in the face of a diminishing toolbox of antimicrobial products. They connect academic research, industrial innovation, and federal support in a way that can actually reach producers.”
The SEAPF consortium brings together expertise in genomics, bioinformatics, microbiology, and biomanufacturing. Public investment through AAFC is expected to generate Canadian intellectual property, support highly qualified jobs in British Columbia, and reduce reliance on imported antimicrobial technologies.
“By investing in next-generation antimicrobials for agriculture, Canada is taking practical steps to implement its commitments on AMR while supporting innovation-driven growth in our agri-food sector.”
The SEAPF Project will run through March 2028, with key milestones including the delivery of flexible production methods for lead candidates and a defined manufacturing pathway. The project is designed to create a platform that can ultimately be extended to additional livestock species and export markets.
About Amphoraxe Life Sciences Inc.
Amphoraxe Life Sciences is a Vancouver-based biotechnology company developing antimicrobial peptide therapies and products to address antimicrobial resistance in human and animal health. Working closely with leading academic and clinical partners, Amphoraxe focuses on translating cutting-edge science into practical solutions for patients, providers, and producers.
Media Contact
Fatih Birol
Chief Executive Officer
Amphoraxe Life Sciences Inc.
778-893-4042
fatih@amphoraxe.ca